Related Experiment Video

Updated: May 25, 2026

Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry
12:36

Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry

Published on: June 26, 2018

Integrative continuum: accelerating therapeutic advances in rare autoimmune diseases

Katja Van Herle1, Jacinta M Behne, Andre Van Herle

  • 1Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California 90024, USA. doctor@kvh3.com

Annual Review of Pharmacology and Toxicology
|January 13, 2012
PubMed

Insights

Autoimmune diseases pose a significant health threat. An integrative model is being applied to neuromyelitis optica (NMO) to accelerate the development of new treatments for rare autoimmune disorders.

Area of Science:

  • Immunology
  • Neuroscience
  • Pharmacology

Background:

  • Autoimmune diseases are chronic, life-threatening conditions, representing a growing public health concern.
  • They are among the top 10 causes of death in women, with some diseases exceeding the incidence rates of heart disease and cancer.
  • Limited therapeutic options exist for many autoimmune diseases, particularly rare ones.

Purpose of the Study:

  • To address challenges in drug development for rare autoimmune diseases.
  • To apply an integrative continuum model to neuromyelitis optica (NMO).
  • To accelerate the discovery and application of novel therapeutic strategies.

Main Methods:

  • Utilizing emerging information on molecular and cellular mechanisms.
  • Implementing an integrative continuum model linking target discovery with pharmacologic application.
  • Focusing on neuromyelitis optica (NMO) as a case study for a potentially devastating neurodegenerative process.

Main Results:

  • The integrative continuum model facilitates overcoming drug development obstacles.
  • This approach links target discovery with pharmacologic application to enhance clinical efficacy.
  • Potential for accelerating therapeutic advances in NMO and other rare autoimmune diseases.

Conclusions:

  • Innovative strategies are crucial for advancing treatment in rare autoimmune diseases.
  • The integrative continuum model shows promise in accelerating drug development for conditions like NMO.
  • Further application of this model may lead to improved therapeutic options and patient outcomes.

More Related Videos

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

Related Concept Videos

Autoimmune Disorders01:29

Autoimmune Disorders

Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune system...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...